Abstracts tagged "Comorbidity"

Abstract Number: 1452 • ACR Convergence 2021
COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study
Clio Mavragani¹, Athanasios-Dimitrios Bakasis², Kyriaki Boki³, Athanasios Tzioufas⁴, Panayiotis Vlachoyiannopoulos¹, Ioanna Stergiou⁵, Fotini Skopouli⁶ and Haralampos Moutsopoulos⁷, ¹National and Kapodistrian University of Athens, Athens, Greece, ²1 Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³3 Rheumatology Unit, Sismanoglio General Hospital, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, ⁶Department of Nutrition and Clinical Dietetics, Harokopio University of Athens, Athens, Greece, ⁷Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: The impact of COVID-19 infection in patients with autoimmune/auto-inflammatory rheumatic diseases (AARD) under immunomodulatory treatment is not entirely clear and deeper knowledge is of…
Abstract Number: 0725 • ACR Convergence 2021
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Philip Mease¹, Theresa Mallick-Searle², Elizabeth Johnston³, Lars Viktrup³, Dominique Menuet⁴, Ruoyong Yang⁵ and Robert Fountaine⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford Health Care, Redwood City, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer SAS, Paris, France, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a monoclonal antibody directed against nerve growth factor that is under study to treat moderate to severe chronic pain associated with osteoarthritis…
Abstract Number: 1656 • ACR Convergence 2021
Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study
Hayley Dykhoff¹, Elena Myasoedova¹, Madeline Peterson¹, John Davis¹, Vanessa Kronzer¹, Caitrin Coffey¹, Tina Gunderson¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with RA have an increased burden of multimorbidity. Although many comorbidities vary by sex, sex differences in multimorbidity among individuals with RA have…
Abstract Number: 0798 • ACR Convergence 2021
The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)
Lillian-Ruiheng Chen¹, Orit Schieir², Marie-France Valois³, Janet Pope⁴, Susan Bartlett³, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Narcisse Singbo¹, Vivian Bykerk¹¹ and Louis Bessette¹², ¹Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Comorbid conditions have been shown to negatively influence the achievement of treatment targets in rheumatoid arthritis (RA) patients. The comorbid conditions may bias the…
Abstract Number: 1657 • ACR Convergence 2021
Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
Cynthia Crowson¹, Tina Gunderson², Elena Myasoedova², Elizabeth Atkinson², Vanessa Kronzer², Caitrin Coffey² and John Davis², ¹Mayo Clinic, Eyota, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Multimorbidity is common in patients with rheumatoid arthritis (RA), and it is associated with poor outcomes. The literature on multimorbidity suffers from numerous definitions…
Abstract Number: 0883 • ACR Convergence 2021
Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of osteoporosis, end-stage renal disease, cardiovascular disease, and other comorbidities. The presence of multiple…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 1134 • ACR Convergence 2020
Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases
Katherine Wysham¹, Joshua Baker², Kristin Wipfler³, Sarah Lieber⁴, Sebastian Sattui⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹VA Puget Sound/University of Washington, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Hospital for Special Surgery, New York, NY, ⁵University of California, San Francisco, Novato, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Frailty is associated with poor health outcomes in the general population, and recent studies have highlighted its importance in rheumatic musculoskeletal diseases (RMDs). Prior…
Abstract Number: 0320 • ACR Convergence 2020
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Tal Gazitt¹, Muhanad Abu Elhija¹, Amir Haddad¹, Idit Lavi¹, Muna Elias¹ and Devy Zisman¹, ¹Carmel Hospital, Haifa, Israel
Background/Purpose: To assess the implementation of the “Treat-to-Target” (T2T) concept using validated composite disease activity scores in daily management of psoriatic arthritis (PsA).Methods: A retrospective…
Abstract Number: 1181 • ACR Convergence 2020
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Courtney O'Brien¹, Aman Kugasia², Anna Gorfin³, Lauren Klebek³, Joshlean Fair³ and Joel Block¹, ¹Rush University, Chicago, IL, ²Arthritis Clinic of Cypress and Katy, PA, Katy, TX, ³Rush University, Chicago
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…
Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Maria Elisa Acosta¹, Olga Compán², Sonia Pastor¹, Guadalupe Manzano Canabal¹, Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Olga Martinez Gonzalez⁵, Ana Isabel Turrión¹, Javier Del Pino-Montes¹ and Carlos Montilla Morales¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, ´Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
Abstract Number: 1219 • ACR Convergence 2020
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Piero Ruscitti¹, Onorina Berardicurti¹, Paola Cipriani¹ and Roberto Giacomelli¹, ¹University of L'Aquila, L'Aquila, Italy
Background/Purpose: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets by using biologic DMARDs designed for rheumatoid arthritis (RA), and IL-1…
Abstract Number: 0419 • ACR Convergence 2020
Survival and Prevalent Comorbidities in Polymyalgia Rheumatica
Carl Turesson¹, Ankita Sharma², Charlotta Fors², Jan Åke Nilsson³, Aladdin Mohammad⁴ and Ulf Bergström², ¹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: There is limited information on mortality in patients with polymyalgia rheumatica (PMR), and on prevalent comorbidity at the time of diagnosis of PMR. The…
Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Gillian Fitzgerald¹, George Tomlinson², Steve Ramkissoon³, Sophie Wojcik⁴, Robert Inman⁵ and Nigil Haroon⁶, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴UHN, Montreal, QC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].